3 results on '"Nathan Standifer"'
Search Results
2. 275 Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC
- Author
-
Maria Libera Ascierto, Rajv Raja, Carl Barrett, Melissa de los Reyes, Song Wu, Micheal Oberst, and Nathan Standifer
- Subjects
Tumor microenvironment ,Durvalumab ,business.industry ,medicine.medical_treatment ,Immunotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Immunophenotyping ,Immune system ,medicine.anatomical_structure ,Cancer research ,Medicine ,business ,Tremelimumab ,Memory T cell ,CD8 ,medicine.drug - Abstract
Background Emerging data suggest poor outcome to anti- PD(L)1 blocking agents in patients with STK11mut tumors1. In the current study, we undertook in-depth translational evaluations of three Ph1/Ph2 independent studies of Durvalumab ± Tremelimumab to elucidate the biology associated with STK11 mutations leading to reduced clinical response in patients with non-squamous NSCLC. Methods Mutational status was evaluated by ctDNA or Foundation One CDx as previously described1. RNA sequencing was conducted on baseline frozen biopsies (N=70). Selected proteins (N=66) were measured by Myriad RBM multiplexed immunoassays on baseline serum (n=91). Screening and longitudinal whole blood was assessed for circulating quantities of T, B or NK cells and activated or memory T cell subsets using bioanalytically-validated, flow cytometry-based immunophenotyping assays. Exploratory analyses of translational endpoints according to STK11 mutational status were conducted by Wilcoxon rank-sum test. Results In the periphery, a reduced number (> 2-fold decreased in median quantities) of NK cells, CD4+ effector memory, CD4+ HLA-DR+, CD8+ effector memory and CD8+ HLA-DR+ T cells was observed at baseline and following treatments in patients with STK11mut vs. STK11wt tumors. At baseline, increased levels of IL6 (p=0.002) and the neutrophil-attracting cytokine IL8 (p=0.02) were found in serum of patients with STK11mut tumors. In the tumor microenvironment, significantly increased expression (p 2) of markers associated with neutrophils, (i.e. CXCL2, IL6, CSF3), Th17 contexture (i.e. IL17A) and immune checkpoints (i.e. KIRs, PD-L1) was found in STK11mut vs. STK11wt tumors. Conclusions The poor outcomes to immunotherapy observed in NSCLC patients with STK11mut tumors might be determined by a compromised peripheral and intra-tumoral immune phenotype. These results might help the development of novel therapeutic interventions able to unleash response to immune checkpoints in NSCLC patients harboring STK11 mutations. Trial Registration NCT01693562, NCT02087423, NCT02000947 Reference Jure Kunkel Met al, JCO. 2018.36.15_suppl.3028.
- Published
- 2020
3. 274 Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced non-small cell lung cancer
- Author
-
Song Wu, Matthew D. Hellmann, Han Si, Jean-Charles Soria, Maria Libera Ascierto, Rajiv Raja, Caroline Germa, Nathan Standifer, Chris Morehouse, Carl Barrett, Shaad Essa Abdullah, and Marlon Rebelatto
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunotherapy ,CD38 ,medicine.disease ,Blockade ,Clinical trial ,Immunophenotyping ,Immune system ,Internal medicine ,medicine ,Lung cancer ,business ,CD8 - Abstract
Background Despite the encouraging successes of immune checkpoint inhibitors, many patients do not benefit and are either refractory or relapse. The mechanisms of refractory or relapsed disease following PD-(L)1 blockade are largely unknown. To identify characteristics associated with refractory or relapsed disease we explored the immune and genomic landscape of samples derived from NSCLC patients who previously received PD-(L)1 blockade and had blood and fresh tumor biopsies collected at the time of progression. Methods Patient response categories were defined prospectively; ‘refractory’ defined as progression within 16 weeks of initiating PD-(L)1 and ‘relapse’ defined as initial clinical benefit (CR, PR, SD) followed by progression. RNAseq (n=52) and PD-L1 IHC (n=22) were performed on tumor tissue. Immune profiling of whole blood was assessed using flow cytometry or Biomark HD (Fluidigm) gene expression panel (n=54 and n=62, respectively). Differential gene expression was defined as unadjusted p 1.5. Pathways analysis was conducted by David tool. Patient samples were collected during screening for clinical trial of second line immunotherapy. Written informed consent was obtained from the patients for publication of this abstract. Results In patients with NSCLC previously treated with PD-(L)1 blockade, tumors of relapsed patients were characterized by increased expression of genes associated with interferon signaling (e.g. CXCL9, SPIC, IFNg), immune suppression (e.g. ARG1, TGFB), immune exhaustion (e.g. ADORA2A), and increased PD-L1 expression (by gene expression and IHC). Refractory disease was associated with increased cadherin signaling and calcium-dependent-cell-adhesion gene expression pathways. In the periphery, reduced quantities of B cells and activated (HLA-DR+ or CD38+) or proliferating (Ki67+) CD8+ T cells were observed in refractory patients. Conclusions The tumor and peripheral compartments of patients with NSCLC previously treated with PD-(L)1 blockade differ based on prior response. Relapsed patients tend to have signals of sturdy immune activation and chronic inflammation thus ultimately leading to immune exhaustion. These results may help inform rational therapeutic strategies to overcome resistance to PD-(L)1 blockade in NSCLC. Trial Registration NCT02000947 Ethics Approval Research on human samples here analyzed have been performed in accordance with the Declaration of Helsinki. Consent Written informed consent was obtained from the patient for publication of this abstract.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.